Company: STAA
Filing Date: 2025-12-16
Form Type: DEFA14A
Source: 0001193125-25-320166
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-12-16
Form: DEFA14A
Chunk 1
---
 66% premium to the closing price of STAAR common stock on August 4, 2025. Independent industry analysts have stated:

| • |     | “Healthy premium remains, go-shop complete. The $1.6bn all-in takeout valuation prices the transaction at roughly ~4.5x on a forward EV/Sales basis using our blended 2026-2027 prevailing STAA estimates ($271mn in 2026; $300mn in 2027). This approximate ~4.5x exit 
 multiple is comparable to smid-cap growth peers with a topline growth profile of 10%+ which trade in the 4x to 6x range on ‘26/‘27 estimates. The proposed offer is also in-line with recent deals                                                                      
 across the US Medtech space… Hence, we see the ~4.5x proposed exit multiple as sufficiently fair.” (Mizuho, Dec. 9, 2025)                                                                                                                                               |

In addition, as announced yesterday, independent proxy advisory firm Institutional Shareholder Services (“ISS”) has issued an updated report and now recommends that STAAR stockholders vote “FOR” the Alcon transaction. In its report, ISS states that “uncertainties about valuation are now outweighed by the combination of more acute downside risks and improved terms” 1with respect to the Alcon agreement. The STAAR Board of Directors recommends that stockholders vote “FOR” the Alcon merger on the WHITE proxy card TODAY to protect the value of their investment. STAAR will hold a virtual Special Meeting of Stockholders on December 19, 2025, at 8:30 a.m. (Pacific Time). Stockholders of record as of the close of business on October 24, 2025, are entitled to vote at the meeting. Stockholders with questions about voting their shares should contact STAAR’s proxy solicitor, Innisfree M&A Incorporated:

| • |     | For stockholders: +1 877-750-8233                                              
 (toll-free from the U.S. and Canada) or +1 412-232-3651 (from other countries) |

| • |     | For banks and brokerage firms: +1 
 212-750-5833                      |

| 1 | Permission to use quotations here and throughout neither sought nor obtained |

About STAAR Surgical

STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision